Biotechnology firm Trovagene has submitted a protocol to the US Food and Drug Administration (FDA) for a Phase II clinical trial of PCM-075 to treat metastatic castration-resistant prostate cancer (mCRPC).

PCM-075 is a selective adenosine triphosphate (ATP) competitive inhibitor of the serine/threonine polo-like-kinase 1 (PLK 1) enzyme over-expressed in several hematologic cancers and solid tumours.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The multi-centre, open-label Phase II trial will be carried out in combination with standard dose of abiraterone acetate (Johnson & Johnson’s Zytiga) and prednisone.

Planned to assess the safety and efficacy of oral PCM-075, the trial will enrol around 25 subjects who display signs of early progressive disease while on androgen deprivation therapy (ADT) in conjunction with abiraterone and prednisone.

“Zytiga appears to enhance the PCM-075 mechanism of action of arresting cells during mitosis with subsequent tumour cell death.”

A follow-up will be carried out around every six weeks until disease progression in participants with stable disease or better at the end of treatment evaluation.

Trovagene CEO Bill Welch said: “We are encouraged by our preclinical data demonstrating that the combination of PCM-075 and Zytiga appears to enhance the PCM-075 mechanism of action of arresting cells during mitosis with subsequent tumour cell death.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Filing our Phase II clinical trial protocol with the FDA is an important milestone towards addressing the medical need to extend the benefit of response to Zytiga in patients with mCRPC.”

The firm expects to receive the FDA approval and initiate the Phase II trial next year.

Secondary observation endpoints of the trial include effects of the combination therapy on time to prostate-specific antigen (PSA) progression, radiographic response and progression.